ⓘ Inebilizumab

                                     

ⓘ Inebilizumab

Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. Inebilizumab is currently being tested in a phase 2 study for treating Neuromyelitis Optica Spectrum Disorder. NMOSD is a rare autoimmune disorder in which immune system cells and autoantibodies attack and damage the optic nerves and spinal cord. Clinically, the disease is manifested with attacks/relapses that result in neurological impairment such as blindness, paraplegia, sensory loss, bladder dysfunction, and peripheral pain. The disability from each attack is cumulative, making NMOSD a chronically debilitating and potentially life-threatening disease.

This drug was developed viela bio and MedImmune, LLC.

                                     
  • mab chimeric SDC1 cancer Indusatumab vedotin mab human GUCY2C cancer Inebilizumab mab humanized CD19 cancer, systemic sclerosis, multiple sclerosis Infliximab